Tempest Therapeutics
TPST · Nasdaq · United States
Share price · TPST
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TPST's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026+29.2%
Nothing announced by TPST that day or the session before.
- 21 Sep 2026-20.1%
Nothing announced by TPST that day or the session before.
- 17 Sep 2026-26.0%
- 16 Sep 2026+60.2%
- 10 Sep 2026-11.7%
Nothing announced by TPST that day or the session before.
- 17 Aug 2026+11.3%
Nothing announced by TPST that day or the session before.
- 14 Aug 2026-13.2%
- 11 Aug 2026+13.5%
- Day beforeEarnings date (period ending 2026-06-30)
- 10 Aug 2026+13.5%
- 14 May 2026+13.6%
Share of unusual movement by asset
For each asset, the share of TPST's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Amezalpatevents and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 53% |
| Sessions with no dated event | — | 46% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PPARα (peroxisome proliferator-activated receptor alpha)Small molecule | Hepatocellular Carcinoma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.2M | $0.9M | $3.6M-$2.0M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.8M | $1.2M | $5.2M-$2.8M operating cash flow | report ↗ |
| 2026-Q1 | — | $0.1M | $2.3M | $28M-$7.6M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.6M | $8.0M | $3.5M-$6.8M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.9M | $15M | $7.9M-$8.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.6M | $22M | $11M-$8.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $7.6M | $23M | $11M-$10M operating cash flow | report ↗ |
| 2024-Q2 | — | $5.8M | $32M | $9.6M-$5.5M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.3M | $33M | $7.9M-$7.2M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.2M | $12M | $6.8M-$6.5M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.4M | $18M | $7.6M-$6.4M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.7M | $23M | $7.6M-$8.3M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.0M | $43M | $8.9M-$9.1M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.7M | $52M | $9.2M-$8.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.1M | $46M | $8.5M-$7.1M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $52M | $28M-$8.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.6M | $60M | $8.1M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $13M | $7.7M | $26M | report ↗ |
Tempest Therapeutics reported no revenue for the full year 2025. R&D expense was $12.6M, down 55.8% YoY from $28.5M, and the company ended the year with $7.7M in cash and cash equivalents. Net loss was $26.3M, or $6.33 per share, compared to a net loss of $41.8M, or $19.50 per share, in the prior year.
The company highlighted completion of its strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience, appointment of Matt Angel, Ph.D., as CEO and President, and positive interim data from the REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma, including a 100% complete response rate in six efficacy-evaluable patients. Management also noted potential 2026 milestones, including a U.S. IND submission and initiation of a Phase 2b registrational study for TPST-2003, plus a planned Phase 2 study of TPST-1495 in familial adenomatous polyposis expected to be funded by the National Cancer Institute.
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($1.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-13 | Frederick John W. · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-09-22 | Smith Nancy Freda · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-06-04 | Yee John D. · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-06-04 | Richey William Drake · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-03-31 | Maestas Nicholas · Chief Financial Officer | Award / grant (derivative) | 140,000 | — | — | Form 4 |
| 2026-03-31 | Trojanowski Justin · Corporate Controller | Award / grant (derivative) | 22,000 | — | — | Form 4 |
| 2026-03-24 | Angel Matthew · director, CEO and President, 10% owner | Open-market purchase | 231,482 | $2.16 | $500K | Form 4 |
| 2026-03-24 | Angel Matthew · director, CEO and President, 10% owner | Open-market purchase (derivative) | 231,482 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 21 reporting institutions held 0.5M shares ($848K, 2.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 233,888 | $384K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 86,990 | $143K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 68,908 | $113K |
| 4 | BlackRock, Inc. | 39,068 | $64K |
| 5 | FMR LLC | 33,225 | $54K |
| 6 | SABBY MANAGEMENT, LLC | 17,856 | $29K |
| 7 | NORTHERN TRUST CORP | 14,053 | $23K |
| 8 | DIMENSIONAL FUND ADVISORS LP | 11,444 | $19K |
| 9 | UBS Group AG | 4,533 | $7K |
| 10 | Tower Research Capital LLC (TRC) | 2,790 | $5K |
| 11 | MORGAN STANLEY | 2,058 | $3K |
| 12 | OSAIC HOLDINGS, INC. | 1,529 | $2K |
| 13 | Federation des caisses Desjardins du Quebec | 292 | $479 |
| 14 | JONES FINANCIAL COMPANIES LLLP | 239 | $413 |
| 15 | Vanguard Global Advisers, LLC | 168 | $276 |